Latest1 information on COVID-19

Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy

Not Recruiting

Trial ID: NCT02369835

Age - 18 Years-N/A Condition - Head and Neck Cancers (H&N), H and N - Oral Cancer, H and N - Throat Cancer (Oropharynx, Laryngeal, Hypopharyngeal) Gender - All Accepting Healthy Volunteers - No

Purpose

This randomized phase 3 trial studies how well modified Dakin's solution works in reducing radiation-induced dermatitis, a common skin reaction to radiation therapy, in patients with head and neck cancer undergoing radiation therapy. Modified Dakin's solution may reduce inflammation in the body, which may prevent or reduce dermatitis after radiation therapy. Radiation therapy in this study is regulatory medical care based on the patient's needs and the radiation oncologist's judgment. It is not possible nor necessary to explicitly define the dose or duration of treatment.

Official Title

A Randomized Study of Topical Dilute Hypochlorite (Modified Dakin's Solution) Treatment for the Prevention of Radiation Dermatitis in Head and Neck Cancer

Stanford Investigator(s)

Bernice Kwong, MD
Bernice Kwong, MD

Clinical Professor, Dermatology

Quynh-Thu Le, MD
Quynh-Thu Le, MD

Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)

A. Dimitrios Colevas, MD
A. Dimitrios Colevas, MD

Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)

Susan Knox

Eligibility


Inclusion Criteria:

   - Head and neck cancer who plan to undergo radiation therapy to the head and neck region

   - At least 18 years of age

   - Able to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

   - Prior radiation therapy to the head and neck region or prior chemotherapy for head and
   neck cancer (induction chemotherapy NOT excluded)

   - The physician-approved radiation treatment plan indicates a maximum prescription dose
   of less than 45 Gy

   - Scleroderma or discoid lupus

View More
View Less

Intervention(s):

drug: Dakin's solution

other: Placebo

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061

New Trial Alerts

Receive email alerts when trials open to patients.

©2022 Stanford Medicine